Taking a pill can effectively treat brutal lung disease

August 7, 2018, Cincinnati Children's Hospital Medical Center
Alveolar macrophages from the lung of a patient with a disease called autoimmune pulmonary alveolar proteinosis (PAP). The red in the macrophage cells indicates an excess accumulation of cholesterol. Researchers report in Nature Communications cholesterol accumulation is triggered by disrupted cell regulation from a molecule called granulocyte-macrophage colony stimulating factor (GM-CSF). It results in the thick build-up of a substance called surfactant that hinders breathing. The study also shows that taking cholesterol-blocking statins orally can effectively treat PAP. Credit: Cincinnati Children's

Researchers report in Nature Communications they figured out why air sacs in the lungs clog up with a thick substance called surfactant in a brutal disease called Pulmonary Alveolar Proteinosis (PAP), and they show taking cholesterol-busting pills called statins can effectively treat the disease.

That's good news for people with PAP because at present the current standard treatment is something called a whole lung lavage. Essentially, it involves flushing patient lungs to clear out the gunk—a procedure so invasive it requires putting people under general anesthesia. Furthermore, the procedure has to be repeated every time the lungs clog up, which translates into some pretty serious quality of life issues for .

Researchers at Cincinnati Children's Hospital Medical Center found out the culprit is cholesterol. Led by Bruce Trapnell, MD, director of the Translational Pulmonary Science Center, the team found out years ago that PAP is linked to disruption of by a molecule called granulocyte-macrophage colony stimulating factor (GM-CSF). GM-CSF is crucial for the development of fully mature macrophage in the lungs, which are needed to clear away used surfactant—a substance important to lung function—so that people can breathe.

In their new study of PAP patients and mouse models of the disease, the researchers uncovered a more precise reason that disruption of cell regulation by GM-CSF triggers PAP. It's because cell dysregulation reduces the ability of macrophages to process and clear out cholesterol, allowing its levels to build up. This contributes to the accumulation of surfactant that causes PAP and hinders breathing, according to study authors.

"Showing that the pathogenic driver of the disease is disruption of cholesterol homeostasis in these patients will change thinking in the PAP field," explains Trapnell. "Now that we know cholesterol in macrophages is a target for therapeutic development, repurposing statins is a pretty straight forward pharmacological approach for treating people with PAP."

Clinical Trial Planned

The findings are expected to lead to a clinical trial to test statin therapy in larger numbers of people suffering from PAP, said Trapnell. The current study tested statin therapy in two adult patients and in genetically engineered mouse models of PAP.

In both human patients and animal models of PAP, stain therapy was associated with improved cholesterol balance in pulmonary and allowed surfactant to be cleared from . This improved respiratory function in the adult patients and in the laboratory models. Those tests were the result of earlier experiments on mouse pulmonary macrophages and cells donated from patients.

Explore further: Researchers develop novel gene / cell therapy approach for lung disease

More information: Cormac McCarthy et al, Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis, Nature Communications (2018). DOI: 10.1038/s41467-018-05491-z

Related Stories

Researchers develop novel gene / cell therapy approach for lung disease

October 1, 2014
Researchers developed a new type of cell transplantation to treat mice mimicking a rare lung disease that one day could be used to treat this and other human lung diseases caused by dysfunctional immune cells.

Synthetic surfactant could ease breathing for patients with lung disease and injury

July 9, 2018
Human lungs are coated with a substance called surfactant which allows us to breathe easily. When lung surfactant is missing or depleted, which can happen with premature birth or lung injury, breathing becomes difficult. ...

When push comes to shove: Airway cells propel liver cancer spread to lungs

June 4, 2018
Hepatocellular carcinoma (HCC) is the most common form of liver cancer, and the third biggest cause of death from cancer worldwide. Although HCC patients have benefited from recent improvements in diagnoses and various therapies, ...

Study identifies new molecular target for treating deadly lung disease IPF

April 10, 2018
Scientists searching for a therapy to stop the deadly and mostly untreatable lung disease, idiopathic pulmonary fibrosis (IPF), found a new molecular target that slows or stops the illness in preclinical laboratory tests.

Pulmonary fibrosis caused by single transcription factor

December 26, 2017
To date, the molecular basis of pulmonary fibrosis has been poorly understood. Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now shown that reduced activity of the transcription ...

Recommended for you

Increasing statins dose and patient adherence could save more lives

December 7, 2018
Thousands of heart attacks and deaths from cardiovascular disease could be prevented by patients taking higher doses of statins and taking the drugs as advised by doctors.

Progress made in transplanting pig hearts into baboons

December 6, 2018
A large team of researchers from several institutions in Germany, Sweden, Switzerland and the U.S. has transplanted pig hearts into baboons and kept them alive for an extended period of time. In their paper published in the ...

Obesity ups survival in heart failure, but that's no reason to pile on pounds

December 6, 2018
(HealthDay)—Obese people with heart failure may live longer than those who are thinner—especially if they are "metabolically healthy," a new study suggests.

New genetic insight could help treat rare debilitating heart and lung condition

December 6, 2018
The largest study of genetic variation in patients with pulmonary arterial hypertension has associated two important genes with the disease.

New drug target discovered for potential blood pressure treatment

December 5, 2018
Scientists have identified a key player in blood pressure regulation and have shown that switching it off reduces blood pressure in mice, according to new research in eLife.

Neighborhoods with more green space may mean less heart disease

December 5, 2018
People who live in leafy, green neighborhoods may have a lower risk of developing heart disease and strokes, according to new research published in the Journal of the American Heart Association, the Open Access Journal of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.